The closing price of Globus Medical Inc (NYSE: GMED) was $51.87 for the day, down -6.29% from the previous closing price of $55.35. In other words, the price has decreased by -$3.48 from its previous closing price. On the day, 2936427 shares were traded. GMED stock price reached its highest trading level at $55.31 during the session, while it also had its lowest trading level at $51.21.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our analysis of GMED’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.56 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 42.50. For the most recent quarter (mrq), Quick Ratio is recorded 2.72 and its Current Ratio is at 4.88. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.13.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, ROTH MKM on October 20, 2023, initiated with a Buy rating and assigned the stock a target price of $75.
On September 19, 2023, Stifel Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $61.
Canaccord Genuity Upgraded its Hold to Buy on March 30, 2023, while the target price for the stock was maintained at $67.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 01 ’24 when Huller Kelly sold 7,500 shares for $54.10 per share. The transaction valued at 405,730 led to the insider holds 0 shares of the business.
Lemaitre Dan sold 43,450 shares of GMED for $2,475,977 on May 15 ’23. The Director now owns 10,800 shares after completing the transaction at $56.98 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GMED now has a Market Capitalization of 7.02B and an Enterprise Value of 7.02B. As of this moment, Globus’s Price-to-Earnings (P/E) ratio for their current fiscal year is 44.54, and their Forward P/E ratio for the next fiscal year is 15.69. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.75. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.48 while its Price-to-Book (P/B) ratio in mrq is 1.77. Its current Enterprise Value per Revenue stands at 4.48 whereas that against EBITDA is 20.27.
Stock Price History:
Over the past 52 weeks, GMED has reached a high of $62.88, while it has fallen to a 52-week low of $43.38. The 50-Day Moving Average of the stock is 54.12, while the 200-Day Moving Average is calculated to be 53.31.
Shares Statistics:
GMED traded an average of 1.17M shares per day over the past three months and 971.86k shares per day over the past ten days. A total of 113.91M shares are outstanding, with a floating share count of 112.00M. Insiders hold about 17.26% of the company’s shares, while institutions hold 80.18% stake in the company. Shares short for GMED as of Feb 29, 2024 were 5.73M with a Short Ratio of 4.91, compared to 5.32M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.24% and a Short% of Float of 5.12%.
Earnings Estimates
The firm’s stock currently is rated by 15 analysts. On average, analysts expect EPS of $0.57 for the current quarter, with a high estimate of $0.62 and a low estimate of $0.49, while EPS last year was $0.53. The consensus estimate for the next quarter is $0.66, with high estimates of $0.69 and low estimates of $0.63.
Analysts are recommending an EPS of between $2.72 and $2.67 for the fiscal current year, implying an average EPS of $2.69. EPS for the following year is $3.29, with 15 analysts recommending between $3.9 and $3.06.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 14 analysts. It ranges from a high estimate of $598.49M to a low estimate of $566.4M. As of the current estimate, Globus Medical Inc’s year-ago sales were $276.69M, an estimated increase of 111.90% from the year-ago figure. For the next quarter, 14 analysts are estimating revenue of $616.4M, an increase of 111.40% less than the figure of $111.90% in the same quarter last year. There is a high estimate of $623M for the next quarter, whereas the lowest estimate is $606.4M.
A total of 15 analysts have provided revenue estimates for GMED’s current fiscal year. The highest revenue estimate was $2.48B, while the lowest revenue estimate was $2.44B, resulting in an average revenue estimate of $2.46B. In the same quarter a year ago, actual revenue was $1.57B, up 57.10% from the average estimate. Based on 15 analysts’ estimates, the company’s revenue will be $2.65B in the next fiscal year. The high estimate is $2.71B and the low estimate is $2.61B. The average revenue growth estimate for next year is up 7.50% from the average revenue estimate for this year.
